Enrollment Temporarily Closed
This study is temporarily closed to new enrollments. Please contact the study team for more information or check back frequently.

Merck-U02-Substudy 02A_PD-1 Refractory Melanoma - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if combining pembrolizumab and different experimental drugs are safe and effective treatments for people with melanoma that does not improve after standard therapy.

What is the Condition Being Studied?

PD-1 (Programmed Cell Death Protein 1) Resistant Melanoma

Who Can Participate in the Study?

Adults ages 18+ who:
- Are diagnosed with melanoma
- Did not respond to previous treatment that used anti-PD-1/L1 therapy

For more information about who can be in this study, please contact the study team at ivy.belskie@duke.edu.

Age Group

What is Involved?

The study is divided into two periods: a screening period and a study dosing period.

If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have other tests done to assess your eligibility

The screening period will last for about one month.

If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned (fair, 50/50 chance) to 1 of 2 groups
-- Group 1 will get pembrolizumab combined with two study drugs called MK-1308 and MK-7684
-- Group 2 will get pembrolizumab combined with lenvatinib and MK-1308

Study Details

Full Title
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma-Substudy 02A
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107343
NCT: NCT04305041
Phase I/II
Enrollment Status
Enrollment Temporarily Closed
Contact the Duke Recruitment Innovation Center